Pharma BD Deal Intelligence
On June 2, 2026, Travere Therapeutics entered an exclusive license and collaboration agreement with Everest Medicines for civorebrutinib (EVER001), an investigational oral covalent reversible BTK inhibitor for immune-mediated rare kidney diseases. Travere obtains rights in all countries outside Greater China and certain East/Southeast Asian markets (which Everest retains). Travere pays $112.5 million upfront and Everest is eligible for up to approximately $1.03 billion in clinical, regulatory and commercial milestones across up to five indications, plus tiered high-single-digit to double-digit royalties — total potential value of roughly $1.14 billion. A ten-year mutual non-compete on competing BTK products applies, subject to change-of-control exceptions. The asset extends Travere's rare kidney disease platform alongside Filspari.